The primary benefit of blinatumomab is its ability to target and eliminate cancer cells with high specificity, leading to potentially better outcomes for patients with certain types of leukemia. Its unique mechanism of action provides a valuable option for patients who may not respond to traditional chemotherapy or who have relapsed after initial treatment.
